Download PDF

1. Company Snapshot

1.a. Company Description

LifeMD, Inc.operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States.The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers.


It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents.LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels.The company was formerly known as Conversion Labs, Inc.


and changed its name to LifeMD, Inc.in February 2021.LifeMD, Inc.


was founded in 1994 and is headquartered in New York, New York.

Show Full description

1.b. Last Insights on LFMD

LifeMD, Inc.'s recent performance was negatively impacted by a quarterly loss of $0.06 per share, lagging revenue estimates. The company faced allegations of issuing misleading business information, prompting investigations by law firms, including Rosen Law Firm, Levi & Korsinsky, and Glancy Prongay & Murray LLP. These investigations concern potential securities law violations. Additionally, the company's Q2 earnings release on August 5, 2025, revealed a loss, contributing to the negative sentiment. Multiple class-action lawsuits have been filed on behalf of shareholders who suffered losses.

1.c. Company Highlights

2. LifeMD's Q3 Earnings: A Strong Step Towards Pure-Play Virtual Care

LifeMD reported a robust third-quarter financial performance, with telehealth revenue increasing 18% year-over-year to $47.3 million, and adjusted EBITDA growing 30% to $2.9 million. Consolidated revenue grew 13% to $60.2 million, with a gross margin of 88%. The company's GAAP net loss attributable to common stockholders was $4.6 million, or a loss of $0.10 per share, missing analyst estimates of a loss of $0.06 per share. The revenue growth was driven by the RexMD business, which returned to growth, adding approximately 10,000 net new subscribers.

Publication Date: Nov -30

📋 Highlights
  • Telehealth Revenue Growth:: Increased 18% YoY to $47.3M, with adjusted EBITDA rising 30% to $2.9M.
  • Regulatory Milestone:: Secured approval for non-sterile 503-A compounding pharmacy, enabling scalable personalized medication production.
  • Weight Management Segment:: Contributes over 50% of total revenue, with branded therapy new patient sign-ups exceeding 50%.
  • 2025 Guidance:: Full-year revenue projected at $192–193M (24% growth) and adjusted EBITDA of $13.5–14.5M (254% growth).
  • Customer Acquisition Cost Reduction:: 33% decline in CPA after expanding insurance coverage, driven by insured customer mix shift.

Operational Highlights

The company secured regulatory approval for its non-sterile 503-A compounding pharmacy, a major milestone that will expand its ability to produce personalized medications at scale. LifeMD also divested its majority interest in WorkSimpli, strengthening its balance sheet and allowing it to operate as a pure-play virtual care and pharmacy company. The divestiture is expected to have a positive impact on the company's financials, enabling it to focus on its core business.

Weight Management Business

More than 50% of the company's total revenue mix comes from its weight management business, with over half of new patient sign-ups coming in through branded therapy. LifeMD expects to capitalize on growth heading into next year, driven by better pricing for branded therapies and product innovation. The company recently announced a reduced price for Wegovy and Ozempic, with self-pay patients able to access these medications for $199 for the first two doses, a 60% reduction from current prices.

Guidance and Outlook

The company provided guidance for the fourth quarter, expecting revenue in the range of $45 million to $46 million, with adjusted EBITDA in the range of $3 million to $4 million. For the full year 2025, LifeMD expects revenue in the range of $192 million to $193 million and adjusted EBITDA in the range of $13.5 million to $14.5 million, representing growth of 24% for revenue and 254% for adjusted EBITDA versus 2024. Analysts estimate next year's revenue growth at -5.4%.

Valuation Metrics

LifeMD's current valuation metrics indicate a P/S Ratio of 0.77 and an EV/EBITDA of 15.84. The company's ROE is 222.28%, and ROIC is 98.97%. These metrics suggest that the market is pricing in significant growth expectations, but the current valuation may be justified given the company's improving financial performance and growth prospects.

3. NewsRoom

Card image cap

LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME's America's Growth Leaders of 2026

Nov -24

Source: globenewswire.com

Card image cap

Benzinga Bulls And Bears: Nvidia, Webull, Netflix — And Tech Stocks Face Worst Sell-Off Since April

Nov -22

Source: feeds.benzinga.com

Card image cap

TDOC vs. LFMD: Which Telehealth Stock Is Better for Your Portfolio?

Nov -20

Source: zacks.com

Card image cap

LifeMD, Inc. (LFMD) Q3 2025 Earnings Call Transcript

Nov -18

Source: seekingalpha.com

Card image cap

LifeMD, Inc. (LFMD) Reports Q3 Loss, Misses Revenue Estimates

Nov -17

Source: zacks.com

Card image cap

LifeMD Stock Plummets After Q3 Earnings: Here's Why

Nov -17

Source: benzinga.com

Card image cap

LifeMD Reports Third Quarter 2025 Results

Nov -17

Source: globenewswire.com

Card image cap

LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk

Nov -17

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (20.29%)

6. Segments

Telehealth

Expected Growth: 24.6%

Telehealth growth driven by increasing adoption of virtual care, expanded insurance coverage, and rising demand for convenient, cost-effective healthcare services. Additionally, COVID-19 pandemic has accelerated the shift towards remote healthcare, further fueling growth. LifeMD's strong brand presence, user-friendly platform, and strategic partnerships have also contributed to its 24.6% growth.

WorkSimpli

Expected Growth: 12.47%

WorkSimpli's 12.47% growth is driven by increasing adoption of telemedicine, rising healthcare costs, and an aging population. Additionally, the platform's user-friendly interface, seamless integration with existing systems, and robust analytics capabilities have contributed to its success. Furthermore, LifeMD's strategic partnerships and expanding provider network have enhanced WorkSimpli's reach and credibility in the market.

7. Detailed Products

RheumRapid

A rapid response treatment for rheumatoid arthritis, providing fast and effective relief from symptoms.

Nurx

A telemedicine platform providing convenient and discreet access to medical consultations and prescription treatments for sensitive health issues.

Yaqua

A line of skincare products harnessing the power of natural ingredients to promote healthy, glowing skin.

Femtest

A convenient and accurate at-home testing kit for women's health, providing insights into hormonal balance and reproductive health.

8. LifeMD, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

LifeMD, Inc. operates in a highly competitive market, but the threat of substitutes is mitigated by the company's strong brand recognition and customer loyalty.

Bargaining Power Of Customers

LifeMD, Inc. has a large customer base, but the bargaining power of customers is high due to the availability of alternative healthcare services.

Bargaining Power Of Suppliers

LifeMD, Inc. has a diversified supplier base, which reduces the bargaining power of suppliers and minimizes the risk of supply chain disruptions.

Threat Of New Entrants

The threat of new entrants in the healthcare industry is moderate, as it requires significant capital investment and regulatory compliance.

Intensity Of Rivalry

The healthcare industry is highly competitive, and LifeMD, Inc. faces intense rivalry from established players and new entrants.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 84.33%
Debt Cost 10.88%
Equity Weight 15.67%
Equity Cost 10.88%
WACC 10.88%
Leverage 537.99%

11. Quality Control: LifeMD, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
NHC

A-Score: 5.9/10

Value: 5.4

Growth: 4.8

Quality: 6.5

Yield: 5.0

Momentum: 6.0

Volatility: 8.0

1-Year Total Return ->

View Full Report
Stock-Card
Patterson Companies

A-Score: 5.3/10

Value: 6.5

Growth: 3.7

Quality: 5.6

Yield: 3.0

Momentum: 9.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
LifeMD

A-Score: 4.9/10

Value: 6.2

Growth: 7.3

Quality: 6.4

Yield: 0.0

Momentum: 8.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Collegium Pharmaceutical

A-Score: 4.9/10

Value: 5.3

Growth: 8.7

Quality: 6.1

Yield: 0.0

Momentum: 3.5

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Innoviva

A-Score: 4.7/10

Value: 4.9

Growth: 5.4

Quality: 6.6

Yield: 0.0

Momentum: 3.0

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
MEI Pharma

A-Score: 4.5/10

Value: 7.6

Growth: 4.8

Quality: 5.2

Yield: 5.0

Momentum: 3.0

Volatility: 1.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.53$

Current Price

3.54$

Potential

-0.00%

Expected Cash-Flows